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Aims/Introduction: Chronic inflammation of the liver is often observed with obesity
or type 2 diabetes. In these pathological conditions, the immunological cells, such as
macrophages, play important roles in the development or growth of liver cancer. Recently,
it was reported that hypoxia-inducible factor-1a (HIF-1a) is a key molecule for the acquisi-
tion of inflammatory M1 polarity of macrophages. In the present study, we examined the
effects of altered macrophage polarity on obesity- and diabetes-associated liver cancer
using macrophage-specific HIF-1a knockout (KO) mice.
Materials and Methods: To induce liver cancer in the mice, diethylnitrosamine, a chem-
ical carcinogen, was used. Both KO mice and wild-type littermates were fed either a high-fat
diet (HFD) or normal chow. They were mainly analyzed 6 months after HFD feeding.
Results: Development of liver cancer after HFD feeding was 45% less in KO mice than
in wild-type littermates mice. Phosphorylation of extracellular signal-regulated kinase 2 was
also lower in the liver of KO mice. Those effects of HIF-1a deletion in macrophages were
not observed in normal chow-fed mice. Furthermore, the size of liver tumors did not differ
between KO and wild-type littermates mice, even those on a HFD. These results suggest
that the activation of macrophage HIF-1a by HFD is involved not in the growth, but in
the development of liver cancer with the enhanced oncogenic extracellular signal-regu-
lated kinase 2 signaling in hepatocytes.
Conclusions: The activation of macrophage HIF-1a might play important roles in the
development of liver cancer associated with diet-induced obesity and diabetes.
INTRODUCTION
Liver cancer is one of the representative cancers whose inci-
dence increases in patients suffering from metabolic diseases,
such as obesity and type 2 diabetes1–3. The development of
liver cancer is considered to be related to chronic inflammation.
For example, it develops more frequently in patients with
chronic hepatitis or liver cirrhosis induced by hepatitis virus
infection4,5. Recently, Karin’s group showed that the activation
of tumor necrosis factor or interleukin (IL)-6 signaling is
involved in the development of obesity- and diabetes-associated
liver cancers using mouse models totally lacking these cytoki-
nes6. In addition, Ohtani et al. reported that enhanced IL-6
signaling in stellate cells also plays an important role for obe-
sity- and diabetes-induced liver cancer. Alteration of intestinal
bacteria flora by diet-induced obesity and diabetes increases
the production of deoxycholate, which is involved in enhanced
IL-6 signaling in stellate cells7. These results suggest that
obesity- and diabetes-associated alterations in the environmen-
tal factors possibly affect the functions not only in hepatocytes,Received 6 September 2018; revised 12 March 2019; accepted 15 March 2019
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parenchymal cells in the liver, but also in the stromal cells, thus
indirectly increasing the incidence of liver cancer. However, the
indirect effects of the environmental factors on stromal cells are
less understood than the direct effects on hepatocytes8.
Among the stromal cells that are able to affect the functions
of cancer, most studies focus on the roles of tumor-associated
macrophages (TAMs) existing inside and outside of the cancers.
For example, when a large number of TAMs exist in liver can-
cer, the prognosis of the patients becomes worse9,10, suggesting
that TAMs possibly affect the development and/or growth of
liver cancers. Because macrophages have great variety and plas-
ticity in general, the characteristics of macrophages are
expressed between the two polarities of classically activated M1
and alternatively activated M2. Recent studies have presented a
simple model of the functional relationship between TAMs and
cancer; that is, TAMs show an inflammatory M1 polarity, and
they work against the development and growth of cancers in
the earlier phases of the carcinogenic process. Then, TAMs
develop an anti-inflammatory M2 polarity, and they stimulate
the growth and/or metastasis of the cancer in the middle or
later phases of the carcinogenesis11,12.
Recently, Takeda et al.13 reported that the activation of
hypoxia-inducible factor-1a (HIF-1a) in macrophages plays a
critical role in the induction of M1 polarity, whereas HIF-2a is
important for the acquisition of M2 polarity. We have recently
reported that adipose tissue hypoxia observed in obese mice is
associated with the induction of M1 polarity of adipose tissue
macrophages by activating the HIF-1a of the cells14,15. Because
cancers also increase their volume very rapidly and pathologi-
cally as adipose tissue of obese animals does, we hypothesized
that HIF-1a in TAMs existing inside or outside of liver cancer
might play some role in the induction of macrophage polarity
and the development or growth of the cancer.
In the present study, we used diethylnitrosamine (DEN), a
chemical carcinogen, to induce liver cancer. Because the inci-
dence of DEN-induced liver cancer in mice is reported to be
increased by high-fat diet (HFD)-induced obesity and diabetes6,
we considered it to be a good model for investigating the
mechanisms for obesity- and diabetes-associated carcinogenesis.
Using this carcinogenic method, we analyzed macrophage-spe-
cific HIF-1a knockout (KO) mice, in which we recently
reported that the deletion efficiency of HIF-1a protein in mye-
loid cells was >90%14,15. Here, we show that HIF-1a in macro-
phages plays an important role in the enhanced development
of liver cancer associated with diet-induced obesity and dia-
betes.
METHODS
Generation and maintenance of mice
Homozygous mouse with HIF-1a-deficient monocytes and
macrophages (HIF-1aflox/flox/LysM-Cre; KO) was generated by
crossing a C57BL/6J mouse containing loxP sequences on either
side of the Hif1a gene with a C57BL/6J mouse expressing Cre
recombinase under the lysozyme M (LysM) promoter as
described previously15,16. Mice containing the floxed Hif1a
allele, which did not express the Cre recombinase (HIF-1aflox/
flox), were used as the control. Liver tumor was induced by
injecting 15-day-old male mice with 25 mg/kg of DEN (Sigma,
St. Louis, MO, USA) intraperitoneally. KO mice and control
mice were fed either a normal chow diet (NC) or a HFD con-
taining 60% of its calories from fat (Research Diets Inc., New
Brunswick, NJ, USA) for 6 or 8 months (Figure S1). The ani-
mal care policies and procedures/protocol used in the experi-
ments were approved by the Animal Experiment Ethics
Committee of the University of Toyama (Toyama, Japan).
Liver tumor analysis
After the liver was removed from the mice, the number of
tumors appearing on the surface of the liver that were >1 mm
in diameter was counted. The tumor size was determined as
the maximal axis of each tumor.
Magnetic activated cell sorting and quantitative real-time
polymerase chain reaction
Magnetic activated cell sorting of liver macrophages was carried
out as previously described14,15,17, with some modifications.
Briefly, liver samples were minced and filtered by using a 40-lm
nylon cell strainer (BD Biosciences, Franklin Lakes, NJ, USA) to
remove cell clusters and debris. After counting cell numbers, F4/
80-positive fraction was separated using a MicroBeads Kit with
anti-F4/80 microbeads according to the manufacturer’s protocol
(Miltenyi Biotech, Auburn, CA, USA). After extracting total
ribonucleic acid from F4/80-positive liver macrophages, gene
expression was analyzed by using the Mx3000P QPCR System
(Agilent Technologies, Santa Clara, CA, USA) as previously
described14,15,17. Messenger ribonucleic acid expressions of the
genes were calculated relative to 18S, and they were presented as
values relative to those for control mice.
Immunoblotting
Immunoblotting of liver samples was carried out as described
previously14,15. Briefly, liver samples were frozen in liquid nitro-
gen and preserved until they were used for immunoblotting.
Tissues were homogenized in lysis buffer with 1% Nonidet P-
40 using a Multi-Beads ShockerTM (Yasui Kikai, Osaka-city,
Osaka, Japan) cell disrupter. Cell lysate was run on 7.5% sepa-
rating gel and transferred to polyvinylidene fluoride transfer
membrane. Membranes were incubated with anti-extracellular
signal-regulated kinase 2 (ERK2), anti-phosphorylated ERK2
and anti-b-actin antibodies (Cell Signaling Technology, Dan-
vers, MA, USA). The intensities of the bands were quantified
using a LumiVision Analyzer (Aisin, Kariya, Japan).
Hypoxia probe administration and immunohistochemistry
Immunohistochemistry for the hypoxia probe was carried out
using the Hypoxyprobe-1 plus kit (Hypoxyprobe, Burlington,
MA, USA) as we described previously13,14. Pimonidazole, a
hypoxia probe, was intraperitoneally injected at a dose of
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60 mg/kg bodyweight at 30 min before tissue collection. Liver
samples were processed as histological sections and immunohis-
tochemical analysis with anti-pimonidazole or ant-MAC2 anti-
body as previously described14,15,17,18.
Statistical analysis
The statistical analysis was carried out using the Student’s t-test
or a two-factor ANOVA and post-Tukey–Kramer test. Differences
were considered statistically significant at P < 0.05. The results
were presented as the mean – standard error of the mean.
RESULTS
Myeloid cell-specific HIF-1a deletion did not affect
bodyweight and liver weight
In the present study, we generated a DEN-induced liver tumor
model using myeloid cell-specific HIF-1a KO mice and their
wild-type littermates (WT) to clarify how HIF-1a in macro-
phages affects the development of liver cancer. Both KO mice
and WT were fed either HFD or NC for 6 or 8 months from
1.5 months-of-age (Figure S1). Myeloid cell-specific HIF-1a
deletion did not affect bodyweight, liver weight or fasting blood
glucose levels both in NC-fed and HFD-fed mice during the
time periods (Figure S2).
Myeloid cell-specific HIF-1a deletion decreased the number of
liver tumors only in HFD-fed mice
HFD treatment for up to 6 months increased the number, inci-
dence and size of DEN-induced liver tumors compared with
NC-fed WT mice (Figure 1a). Myeloid cell-specific HIF-1a
deletion decreased the number of liver tumors (Figure 1a,b),
whereas it did not affect the incidence and size of the tumors







































































Figure 1 | Myeloid cell-specific hypoxia-inducible factor-1a deletion decreased the number of liver tumors only in high-fat diet-fed (HFD) mice.
Myeloid cell-specific hypoxia-inducible factor-1a knockout mice (KO) and wild-type littermates (WT) were fed a HFD or normal chaw (NC).
(a) Representative pictures of the liver from WT and KO mice 6 months after HFD or NC feeding. Scale bar, 1 cm. (b, c) The (b) number and
(c) incidence of the tumors were measured after the indicated months of HFD feeding. Open diamond or open column stands for KO, whereas
closed square or closed column for WT; n = 8. The results are shown as the mean – standard error of the mean. (d) The tumor size was
measured 6 months after HFD feeding; n = 8. *P < 0.05; n.s., not significant compared with the WT control.
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when mice were fed NC, there were no differences in the num-
ber, as well as the incidence and size of liver tumors, between
KO and WT mice (Figure 1a; Figure S4). These results suggest
that myeloid cell HIF-1a, which is possibly activated by HFD
treatment, is involved not in the growth, but in the develop-
ment of liver tumors.
Myeloid cell-specific HIF-1a deletion decreased ERK
phosphorylation in the liver of HFD-fed mice
To investigate the mechanisms of how HIF-1a deletion in mye-
loid cells decreased the development of tumors in HFD-fed
mice, we first examined the phosphorylation of ERK in the
liver, the activation of which was reported to be critical for
DEN-induced carcinogenesis19. As expected, phosphorylation of
ERK was significantly decreased in KO mice by ~60% com-
pared with WT controls (Figure 2). These results showed that
myeloid cell-specific HIF-1a deletion decreased the develop-
ment of tumors with suppressing the ERK pathway in the liver
of HFD-fed mice.
Expression of both M1 and M2 marker genes was decreased
in HIF-1a-deleted macrophages in the liver of HFD-fed mice
To understand the mechanisms of how HIF-1a deletion in
myeloid cells decreased the phosphorylation of ERK (Figure 2)
and the development of liver cancers (Figure 1), we next exam-
ined the polarity of liver macrophages. Macrophages in the liver
were separated from the HFD-fed mice. The expressions of
HIF-1a and its downstream genes, such as glut1 and VEGFA,
were significantly suppressed with 30~40% residual expression
of the WT levels in the KO group (Figure 3a). The expression
of M1 macrophage markers, such as CD11c and IL-1b, was
inhibited by myeloid cell-specific HIF-1a deletion in the liver,
too (Figure 3b). Interestingly, HIF-1a deletion also decreased
the expression of CD206, a representative M2 macrophage
marker (Figure 3c). Some of these marker genes are possibly
related to the activation of mitogenic signaling and tumor
development in the liver.
HIF-1a in macrophages was not activated by hypoxia in the
liver of HFD-fed mice
To examine whether macrophage HIF-1a was activated by
hypoxia in the liver of HFD-fed mice, hypoxia in liver tissue
was evaluated by using antibody against pimonidazole, a
hypoxic probe. Although large numbers of macrophages were
detected with anti-MAC2 antibody both inside and outside of
the tumors, only a few cells were faintly stained with anti-
pimonidazole antibody in the liver of HFD-fed mice (Figure 4;
arrow head). These results suggest that liver macrophages are
not exposed to the hypoxic environment, and that HIF-1a in
macrophages might be activated by some other stimuli than
hypoxia.
It was recently reported that HIF-1a protein is stabilized
when the cells are stimulated with lipopolysaccharide even in
the normoxic condition with accumulating succinate in the
cells20–22. Contrary to our speculation, succinate was not
increased in the liver macrophages in HFD-fed mice, suggesting
that the accumulation of succinate is not the mechanism for
HIF-1a activation (Figure S5).
DISCUSSION
The present study showed that myeloid cell-specific HIF-1a
deletion decreased the number of liver tumors and ERK phos-
phorylation not in NC-fed mice, but in HFD-fed mice. These
results suggest that the activation of macrophage HIF-1a is
involved in those carcinogenic changes in the liver only of
obese and diabetic mice, thus, it is very important to clarify the
mechanisms of how HFD activates HIF-1a in myeloid cells.
Recently, we reported that inflammatory M1 macrophages
are exposed to the most hypoxic area, and they produce
inflammatory cytokines in the adipose tissue of HFD-fed obese
and diabetic mice14,15,23. In the present study, numbers of
macrophages invaded both inside and outside of liver cancers
after the same HFD treatment as that used in our recent studies
















Figure 2 | Myeloid cell-specific hypoxia-inducible factor-1a deletion
decreased extracellular signal-regulated kinase (ERK) phosphorylation in
the liver of high-fat diet-fed (HFD) mice. After HFD treatment for
6 months, immunoblot analysis was carried out using liver samples
from wild-type (WT) and knockout (KO) mice with antibodies against
phosphorylated ERK (p-ERK), ERK and b-actin. Representative pictures
are shown. The intensities of the bands were quantified using a
LumiVision Analyzer. The results are shown as the mean – standard
error of the mean; n = 4. **P < 0.01 compared with WT mice.
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Figure 3 | Myeloid cell-specific hypoxia-inducible factor-1a (HIF-1a) deletion decreased the expression of M1 and M2 marker genes in the liver
macrophages of high-fat diet-fed (HFD) mice. After HFD treatment for 6 months, macrophages in the liver were separated from wild-type (WT)
and knockout (KO) mice by using magnetic microbeads with anti-F4/80 antibody. Total ribonucleic acid was isolated from the liver macrophages,
and real time reverse transcription polymerase chain reaction for the indicated genes was carried out. (a) HIF-1a-related genes, (b) M1 macrophage
marker genes and (c) M2 macrophage marker genes. All data were normalized according to 18S messenger ribonucleic acid level, and presented
as a value relative to that for WT. The results are shown as mean – standard error of the mean for five to eight mice per group. *P < 0.05,
**P < 0.01. Glut1, glucose transporter-1; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; NOS2, nitric oxide synthase 2; TNF, tumor
necrosis factor; VEGF, vascular endothelial growth factor.
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vasculature, cancers also easily suffer from hypoxia, as well as
an expanding white adipose tissue24,25. Thus, we originally
speculated that HIF-1a in macrophages at the cancer site was
activated by local hypoxia. However, in contrast to the M1 adi-
pose tissue macrophages in white adipose tissue, almost no
staining of pimonidazole, a hypoxia probe, could be detected
in the macrophages in the liver of HFD-fed mice (Figure 4).
These results suggest that HIF-1a in the macrophages is acti-
vated by any mechanisms other than local hypoxia in the liver.
Recent studies have shown that HIF-1a protein can keep its
transcriptional activity even in the normoxic condition when
the cells are treated with certain stimuli. For example, when
macrophages are stimulated with lipopolysaccharide, some
metabolites in the tricarboxylic acid cycle, such as succinate, are
accumulated in the cells, which stabilize HIF-1a protein20–22.
Thus, we compared the metabolite levels in liver macrophages
between NC-fed and HFD-fed mice. Contrary to our specula-
tion, succinate was not increased in the liver macrophages in
HFD-fed mice (Figure S5). In this way, the present study could
not show the mechanisms of how HIF-1a in the liver macro-
phages was activated in HFD-fed mice. This is an important
limitation of the present study, and further studies are required
to clarify the mechanism that might be different from local
hypoxia and altered intracellular metabolites.
As shown in Figures 2 and 3, phosphorylation of ERK2, a
well-known growth signal, in the liver (Figure 2), and M1 and
M2 markers in macrophages (Figure 3) was decreased in KO
mice after HFD treatment. Interestingly, the number of macro-
phages in the liver was not significantly different between WT
and KO (data not shown). Therefore, we originally hypothe-
sized that any factors, which are secreted from macrophages in
a HIF-1a-dependent manner, induced the development of liver
cancer by activating the ERK2 signal in hepatocytes. For exam-
ple, because some growth factors, such as epidermal growth
factor26,27, platelet-derived growth factor28,29 and vascular
endothelial growth factor 30–32, are reported to be associated
with the development of liver cancer, we measured their
expressions in the liver of KO mice. However, the expressions
of these growth factors were not suppressed in KO compared
with WT controls (data not shown). Furthermore, deletion of
HIF-1a did not alter insulin levels in fasting conditions (Fig-
ure 1), when we examined the phosphorylation of ERK2 (Fig-
ure 2). Recently, Ohtani et al.7 reported that inflammatory
signaling, such as IL-6 signaling in stellate cells, plays important
roles in the occurrence of liver tumor in obese mouse models.
We also observed that the expression of inflammatory cytokines
was suppressed in the liver macrophages derived from KO mice
(Figure 3). From these results, we speculate that the inflamma-
tory cytokines from liver macrophages might be involved in the
increased development of liver cancer.
In contrast, it is well-known that the alternative activation of

















Figure 4 | Macrophages in the liver of high-fat diet-fed mice was not stained with anti-pimonidazole antibody. After high-fat diet treatment for
6 months, liver tissues of wild type mice were stained with anti-pimonidazole or anti-MAC2 antibody. Representative pictures are shown from four
independent experiments.
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invasion and/or metastasis of cancers. However, it is not fully
understood whether M2 polarity of TAMs is associated with
the development of cancers. Generally, M2 polarity of TAMs is
acquired following the environmental changes after growing of
cancers. In fact, the sizes (growth) of cancers were not altered
in KO mice, when M2 markers were decreased in the present
study. We believe that the contribution of M2 polarity is less
than that of M1 polarity as the mechanism for carcinogenesis,
at least in the case of this study.
In the present study, we showed that HIF-1a in macro-
phages is involved in the activation of growth signaling in hep-
atocytes and the development of liver cancer in HFD-fed mice.
Activation of HIF-1a and the acquisition of inflammatory
polarity of the macrophages were induced by factors other than
local hypoxia in the liver of the obese and diabetic mice. These
results raise a possibility that macrophage HIF-1a might be a
target of prevention or treatment of obesity and diabetes-
associated liver cancer.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.
Figure S1 | Experimental protocol.
Figure S2 | Myeloid cell-specific hypoxia-inducible factor-1a (HIF-1a) deletion did not affect bodyweight, liver weight and fasting
blood glucose level in high-fat diet-fed mice.
Figure S3 | Myeloid cell-specific hypoxia-inducible factor-1a (HIF-1a) deletion did not affect the size of liver tumors in high-fat
diet-fed mice.
Figure S4 | Myeloid cell-specific hypoxia-inducible factor-1a (HIF-1a) deletion did not affect the number, incidence and size of
liver tumors in normal chow-fed mice.
Figure S5 | High-fat diet did not increase succinate accumulation in liver macrophages.
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